Last reviewed · How we verify
NCT05266300
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
trial testing DPYD genotype in Adverse Drug Event in 722 participants. Completed in 1 October 2022.
1 June 2022
Quick facts
| Lead sponsor | University of Southern Denmark |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 722 |
| Start date | 1 September 2020 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 October 2022 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- DPYD genotype
Conditions studied
- Adverse Drug Event — all drugs for Adverse Drug Event →
- Colon Cancer — all drugs for Colon Cancer →
- Breast Cancer — all drugs for Breast Cancer →
- Pancreas Cancer — all drugs for Pancreas Cancer →
Sponsor
University of Southern Denmark
Who can join
18 and older, any sex, with Adverse Drug Event or Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine the benefits of a clinical implementation of a DPYD-genotype test to patients starting treatment with fluoropyrimidines (Fluorouracil (5-FU), capecitabine, tegafur).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Paulsen NH, Pfeiffer P, Ewertz M, Fruekilde PBN, et al · · 2023 · cited 10× · PMID 36791638 · DOI 10.1016/j.esmoop.2023.100782
Verify or expand the search:
- PubMed search for NCT05266300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adverse Drug Event
Currently open trials in the same condition.
- NCT06575530 — Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients · Phase 4 · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
- NCT07164300 — Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery · NA · recruiting
- NCT05084196 — Melatonin for Prevention of Kidney Injury · Phase 3 · recruiting
- NCT05717712 — Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma · Phase 1 · recruiting
Other University of Southern Denmark trials
Trials by the same sponsor.
- NCT07531290 — PeerScreen Trial - Reducing Screen Media Use in Peer-groups of Young People · NA · not yet recruiting
- NCT07384273 — Evaluating the Effectiveness of an Internet-based Therapy (iCARE) to Treat Symptoms of Postpartum Depression · NA · recruiting
- NCT07426679 — Should Anaesthesiologists Be Taught to Perform Ultrasound-- Assisted Neuraxial Access in Spinal Anaesthesia? · NA · recruiting
- NCT07104292 — Pelvic Floor Muscle Training During Pregnancy · NA · recruiting
- NCT07194759 — Health Literacy Levels of Patients Living With Type 2 Diabetes and Multi-disease and Their Families Using HLQTM · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05266300 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern Denmark
- Last refreshed: 1 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05266300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing